Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
2002 1
2005 1
2006 3
2007 4
2008 7
2009 3
2010 5
2011 3
2012 5
2013 4
2014 6
2015 7
2016 7
2017 6
2018 4
2019 5
2020 4
2021 1
2022 3
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
MMRV vaccine safety.
Cashman P, Moberley S, Durrheim D. Cashman P, et al. Vaccine. 2019 Jul 9;37(30):3946. doi: 10.1016/j.vaccine.2018.02.108. Epub 2018 Mar 8. Vaccine. 2019. PMID: 29526373 No abstract available.
Infantile Sweet syndrome following MMRV vaccine.
Itzhaki Gabay S, Samueli B, Test G, Valdman-Grinshpoun Y, Horev A. Itzhaki Gabay S, et al. Pediatr Dermatol. 2023 Jan;40(1):207-209. doi: 10.1111/pde.15162. Epub 2022 Nov 13. Pediatr Dermatol. 2023. PMID: 36373208
We present a case of infantile SS that developed 1 day after the MMRV vaccine; we suggest a possible causal relationship between the MMRV vaccine and SS....
We present a case of infantile SS that developed 1 day after the MMRV vaccine; we suggest a possible causal relationship betwe …
Combined measles-mumps-rubella-varicella vaccine and febrile convulsions: the risk considered in the broad context.
Casabona G, Berton O, Singh T, Knuf M, Bonanni P. Casabona G, et al. Expert Rev Vaccines. 2023 Jan-Dec;22(1):764-776. doi: 10.1080/14760584.2023.2252065. Expert Rev Vaccines. 2023. PMID: 37642012 Free article. Review.
AREAS COVERED: This narrative review contextualizes FC occurrence after the first MMRV vaccine dose from a clinical perspective and outlines approaches to attenuate FC occurrence post-vaccination. ...Based on our findings and considering the MMRV vaccination benefit …
AREAS COVERED: This narrative review contextualizes FC occurrence after the first MMRV vaccine dose from a clinical perspectiv …
Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.
Ma SJ, Li X, Xiong YQ, Yao AL, Chen Q. Ma SJ, et al. Medicine (Baltimore). 2015 Nov;94(44):e1721. doi: 10.1097/MD.0000000000001721. Medicine (Baltimore). 2015. PMID: 26554769 Free PMC article. Review.
A combined measles-mumps-rubella-varicella (MMRV) vaccine is expected to facilitate universal immunization against these 4 diseases. ...
A combined measles-mumps-rubella-varicella (MMRV) vaccine is expected to facilitate universal immunization against these 4 dis …
A New Combined Vaccine Against Measles, Mumps, Rubella and Varicella in India.
Shah N, Parikh R, Casabona G, Kolhapure S. Shah N, et al. Indian Pediatr. 2017 Dec 15;54(12):1041-1046. doi: 10.1007/s13312-017-1209-9. Indian Pediatr. 2017. PMID: 29317560 Free article. Review.
Two doses efficacy, against all varicella is 94.1% and effectiveness reaches 91%. The most frequent solicited local adverse event after MMRV vaccine is redness, and fever is the most common solicited general symptom. ...
Two doses efficacy, against all varicella is 94.1% and effectiveness reaches 91%. The most frequent solicited local adverse event after M …
A combination vaccine against measles, mumps, rubella and varicella.
Knuf M, Faber J, Barth I, Habermehl P. Knuf M, et al. Drugs Today (Barc). 2008 Apr;44(4):279-92. doi: 10.1358/dot.2008.44.4.1210755. Drugs Today (Barc). 2008. PMID: 18536786 Review.
It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. This review presents a summary of the development of this MMRV vaccine from published clinical studies. Seroconversion rates and antibody titers after …
It combines the components from two well-established, live, attenuated vaccines against measles, mumps and rubella. This review presents a s …
Febrile seizures and measles-mumps-rubella-varicella (MMRV) vaccine: what do primary care physicians think?
O'Leary ST, Suh CA, Marin M; Vaccine Policy Collaborative Initiative. O'Leary ST, et al. Vaccine. 2012 Nov 6;30(48):6731-3. doi: 10.1016/j.vaccine.2012.08.075. Epub 2012 Sep 10. Vaccine. 2012. PMID: 22975026
PURPOSE: Measles-mumps-rubella-varicella (MMRV) vaccine is associated with increased febrile seizure risk compared with measles-mumps-rubella and varicella vaccine given separately (MMR+V) in children 12-15-month old. ...
PURPOSE: Measles-mumps-rubella-varicella (MMRV) vaccine is associated with increased febrile seizure risk compared with measle …
Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y, Steri GC, Behre U, Arsène JP, Lanse X, Helm K, Esposito S, Meister N, Desole MG, Douha M, Willems P. Gillet Y, et al. Vaccine. 2009 Jan 14;27(3):446-53. doi: 10.1016/j.vaccine.2008.10.064. Epub 2008 Nov 11. Vaccine. 2009. PMID: 19007835 Clinical Trial.
In this open, randomized, comparative study (105908/NCT00353288), 458 age-stratified children (15 months-2 years and 2-6 years) previously primed with MMR received one dose of either a combined MMRV vaccine (Priorix-Tetra, MMRV group) or concomitant MMR and varicell …
In this open, randomized, comparative study (105908/NCT00353288), 458 age-stratified children (15 months-2 years and 2-6 years) previously p …
78 results